Weight management concerns should be discussed with a qualified healthcare professional before starting any prescription program. Vital Step provides publicly available information outlining how its ...

Elite Force XL is positioned as an all-natural male enhancement formula intended to support free testosterone levels, energy, and physical performance. The product is available as an ...

GloraMD Face Lift Serum is a topical cosmetic serum marketed for the appearance of wrinkles, skin firmness, and hydration using peptide-based ingredients including Palmitoyl Pentapeptide-4, Acetyl ...

The webcast of the presentations will be available on the " Events & Presentations " page of the "Investors" section of the Celldex website. Replays will be available for 90 days following the event.

Effective April 15, 2026, the independent members of the Board of Directors of ImmuCell will be Dr. David Tomsche DVM (Chair), Ms. Gloria Basse, Dr. Anthony DiMarco Ph.D., Dr. Gilles Guillemette DVM, ...

Sana and Mayo Clinic to collaborate across multiple areas with goal of accelerating development of and access to potentially curative therapies for patients with type 1 diabetes.

Kristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a fireside chat on Thursday, April 16 from 3:00 PM to 3:30 PM EDT. Kristen Fortney, Dov Goldstein, MD, CFO, and BJ Sullivan, ...

Allogene announced the futility analysis, which was triggered by the protocol-defined data cutoff of the 24 th patient completing Day 45 minimal residual disease (“MRD”) assessment, showed that 58.3% ...

To Infinity and Beyond for Our Patients,” showcasing the collective stories, innovations, and the vital role of medical laboratory professionals in healthcare. “National Medical Laboratory Week is one ...

Allogene expects to use the net proceeds from this offering for general corporate purposes, which may include clinical trial expenses, research and development expenses, general and administrative ...

Revolution Medicines intends to use the net proceeds from the common stock offering and the note offering for general corporate purposes, including research and development expenses, expenses relating ...

VB4-P5 – novel new chemical entity with potential to address significant unmet need in rare and large-market chronic kidney disease • CALGARY, Alberta, April 13, 2026 (GLO ...